72989-16-3

Basic information

• Product Name: ent-13-(3,4-dimethoxy-benzyl)-4-hydroxy-3β-iodo-19-oxo-ibogamine-18-carboxylic acid lactone
• CAS NO: 72989-16-3
• Molecular Weight: 612.464
• Mol File: 72989-16-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: ent-13-(3,4-dimethoxy-benzyl)-4-hydroxy-3β-iodo-19-oxo-ibogamine-18-carboxylic acid lactone(CAS DataBase Reference)
• NIST Chemistry Reference: ent-13-(3,4-dimethoxy-benzyl)-4-hydroxy-3β-iodo-19-oxo-ibogamine-18-carboxylic acid lactone(72989-16-3)
• EPA Substance Registry System: ent-13-(3,4-dimethoxy-benzyl)-4-hydroxy-3β-iodo-19-oxo-ibogamine-18-carboxylic acid lactone(72989-16-3)

Safety Data

• Hazardous Substances Data: 72989-16-3(Hazardous Substances Data)

Upstream product

• 60706-82-3 ent-4-hydroxy-3β-iodo-19-oxo-ibogamine-18-carboxylic acid lactone 
• 93-03-8 (3,4-dimethoxyphenyl)methanol 

Downstream Products

• 72989-15-2 ent-13-(3,4-dimethoxy-benzyl)-3α,4-epoxy-19-oxo-ibogamine-18-carboxylic acid methyl ester 

Relevant articles and documents

Cytotoxicity of modified indole alkaloids

Indole alkaloids of the iboga series were structurally modified by incorporation of a 3,4-dimethoxybenzyl or -benzoyl unit so that they contained the N-O-O triangle required for antileukemic activity according to the triangulation hypothesis. The cytotoxicities of the modified alkaloids in the in vitro P-388 system were not significantly increased over the unmodified alkaloids, suggesting that the triangulation hypothesis does not apply in this series at least.